Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA394441
Max Phase: Preclinical
Molecular Formula: C11H9ClN2O2
Molecular Weight: 236.66
Molecule Type: Small molecule
Associated Items:
ID: ALA394441
Max Phase: Preclinical
Molecular Formula: C11H9ClN2O2
Molecular Weight: 236.66
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(O)c1cc(Cc2cccc(Cl)c2)n[nH]1
Standard InChI: InChI=1S/C11H9ClN2O2/c12-8-3-1-2-7(4-8)5-9-6-10(11(15)16)14-13-9/h1-4,6H,5H2,(H,13,14)(H,15,16)
Standard InChI Key: UYMDSFKYOCEPFN-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 236.66 | Molecular Weight (Monoisotopic): 236.0353 | AlogP: 2.35 | #Rotatable Bonds: 3 |
Polar Surface Area: 65.98 | Molecular Species: ACID | HBA: 2 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 3.54 | CX Basic pKa: 1.73 | CX LogP: 2.25 | CX LogD: -0.95 |
Aromatic Rings: 2 | Heavy Atoms: 16 | QED Weighted: 0.86 | Np Likeness Score: -1.33 |
1. van Herk T, Brussee J, van den Nieuwendijk AM, van der Klein PA, IJzerman AP, Stannek C, Burmeister A, Lorenzen A.. (2003) Pyrazole derivatives as partial agonists for the nicotinic acid receptor., 46 (18): [PMID:12930155] [10.1021/jm030888c] |
2. Gharbaoui T, Skinner PJ, Shin YJ, Averbuj C, Jung JK, Johnson BR, Duong T, Decaire M, Uy J, Cherrier MC, Webb PJ, Tamura SY, Zou N, Rodriguez N, Boatman PD, Sage CR, Lindstrom A, Xu J, Schrader TO, Smith BM, Chen R, Richman JG, Connolly DT, Colletti SL, Tata JR, Semple G.. (2007) Agonist lead identification for the high affinity niacin receptor GPR109a., 17 (17): [PMID:17588745] [10.1016/j.bmcl.2007.06.028] |
3. Richman JG, Kanemitsu-Parks M, Gaidarov I, Cameron JS, Griffin P, Zheng H, Guerra NC, Cham L, Maciejewski-Lenoir D, Behan DP, Boatman D, Chen R, Skinner P, Ornelas P, Waters MG, Wright SD, Semple G, Connolly DT.. (2007) Nicotinic acid receptor agonists differentially activate downstream effectors., 282 (25): [PMID:17452318] [10.1074/jbc.m701866200] |
Source(1):